Drug profile

The FDA adverse-event record for Bacitracin + Neomycin + Polymyxin B

47 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Bacitracin + Neomycin + Polymyxin B. See the species affected, top reactions, and outcomes below.

47
adverse-event reports
12.8%
death-coded share
Dog
most-reported species
13
Corneal ulcer - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
47
Total Reports
6
Deaths Reported
12.8%
Death Rate

Active Ingredients

BacitracinBacitracin + Neomycin + Polymyxin BNeomycinPolymyxin B

Administration Routes

UnknownOphthalmicTopicalIntraocular

Species Affected

Dog 35
Cat 11
Horse 1

Most Affected Breeds

Domestic Shorthair 9
Crossbred Canine/dog 5
Pug 5
Retriever - Labrador 4
Dog (unknown) 4
Dachshund (unspecified) 3
Maltese 2
Russian 1
Horse (unknown) 1
Retriever - Golden 1

Most Reported Reactions

Corneal ulcer 13
Vomiting 11
Diarrhoea 11
Lethargy (see also Central nervous system depression in Neurological) 9
Ocular discharge 8
Ataxia 7
Other abnormal test result NOS 7
Neurogenic keratoconjunctivitis sicca (KCS) 7
Eye disorder NOS (for Photophobia see neurological) 7
Cloudy eye (for Miosis, Mydriasis, Anisocoria, Nystagmus - see Neurological) 7
Loose stool 6
Nystagmus 6

Outcome Breakdown

Ongoing
25 (53.2%)
Outcome Unknown
13 (27.7%)
Euthanized
4 (8.5%)
Recovered/Normal
3 (6.4%)
Died
2 (4.3%)

Bacitracin + Neomycin + Polymyxin B Adverse Event Insights

47 reports name Bacitracin + Neomycin + Polymyxin B; 6 recorded a death outcome (12.8% of reported events, not a population-level mortality rate). Active ingredients: Bacitracin, Bacitracin + Neomycin + Polymyxin B, Neomycin, Polymyxin B. Administration routes: Unknown, Ophthalmic, Topical, Intraocular.

By species: Dog (35 reports), Cat (11 reports), Horse (1 reports). By breed: Domestic Shorthair (9), Crossbred Canine/dog (5), Pug (5).

Leading clinical signs: Corneal ulcer (13), Vomiting (11), Diarrhoea (11), Lethargy (see also Central nervous system depression in Neurological) (9). Outcome, 47 coded reports: Ongoing leads at 53.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.